groups » Antimalarial drug resistance » Is the widespread use of artemisinin-based combination therapies (ACTs) in malaria-endemic regions sustainable, or should we be focusing more on developing new antimalarial drugs?
Artemisinin-based combination therapies (ACTs) have been the gold standard for malaria treatment since the early 2000s. However, emerging resistance to artemisinin in Southeast Asia has raised concerns about the long-term viability of these drugs. As we continue to rely heavily on ACTs in many parts of the world, particularly in Africa where the malaria burden is highest, we must consider whether this approach is sustainable.
How do we balance improving and utilizing the available resources vs investing in the future solutions
ACTs Antimalarial drug resistance drug development pipelines resource allocation
Please Sign in (or Register) to view further.